ABIO (ARCA Bio) מכפיל P/E עתידי

סמלים רשמיים של חברת ARCA Bio (ABIO)

Revenue and capital dynamics for ARCA Biopharma (ABIO) are subject to reverse merger risks and the binary nature of clinical trials. The company's forward P/E ratio reflects market expectations, where 0.00 represents the latest metric level. The business relies on external laboratories, fully outsourcing its production. Revenue is expected to be generated through innovative drugs targeting atrial fibrillation and cardiological pathologies.

ABIO - מכפיל P/E עתידי ARCA Biopharma, Inc. בטווח 04.07.2022 - 03.09.2024

פילוחים אנליטיים של חברת ARCA Biopharma (ABIO)

- שווי מניות ותחזית קונצנזוס למחירים:
ניתוח בסיסי של החברה:ABIO ARCA Biopharma, Inc.
פריט של המותג ARCA Bio

ARCA Biopharma's strategy of fully outsourcing clinical trials minimizes capital expenditures, directly impacting the projected earnings in the denominator of the valuation formula. The ratio of the current price to expected annual income determines the fundamental margin of safety, which allows for the differentiation of market skepticism from the actual undervaluation of the issuer's assets through the company's calculated forward P/E.